Home > Oncology > A systematic review of interventions to improve AET adherence in breast cancer survivors

A systematic review of interventions to improve AET adherence in breast cancer survivors

Trial
Review study
Physician’s Weekly – 12/10/2023 – The following is a summary of “A Systematic Review and Meta-Analysis of Interventions to Promote Adjuvant Endocrine Therapy Adherence Among Breast Cancer Survivors,” published in the October 2023 issue of Journal of Clinical Oncology by Bright EE, et al.

For a study, researchers sought to conduct a systematic review and meta-analysis of interventions designed to enhance adherence to adjuvant endocrine therapy (AET) among breast cancer survivors. They aimed to provide an up-to-date analysis of these interventions to inform future research and clinical care.

Systematic searches were performed in three electronic databases to identify studies that examined interventions to promote AET adherence among breast cancer survivors. The systematic review included studies that met these criteria. Studies that examined AET adherence measures and provided sufficient information to calculate effect sizes were included in the meta-analysis.

Out of 5,045 unique records, 33 studies representing 375,951 women met the criteria for the systematic review. Interventions that educated patients on managing side effects did not significantly improve AET adherence, while policy changes that reduced AET costs consistently enhanced adherence. Medication reminders, communication, and psychological/coping strategies showed varying efficacy. In the meta-analysis, adherence interventions had a statistically significant effect compared with control conditions specified by the studies (25 studies; odds ratio 1.412; 95% CI 1.183–1.682; P=0.0001). Subgroup analyses showed no significant differences in effect sizes based on study design, publication year, directionality of the intervention, or intervention type.

The study represented the first meta-analysis demonstrating a significant effect of interventions to promote AET adherence among breast cancer survivors. Lowering medication costs and specific psychosocial and reminder interventions showed the most promise. The findings had important implications for future research, policy development, and clinical practice in breast cancer care.

Reference: Bright EE, et al. J Clin Oncol 2023;41(28):4548-4561.

Originally Published By Physician’s Weekly. Reused by Medicom Medical Publishers with permission.

©2023 Physician’s Weekly. All rights reserved. No works may be reproduced without expressed written consent from Physician’s Weekly. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by Physician’s Weekly.



Posted on